Participant flow

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols · Source last updated 2021-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.

   id

   FG000

   title

   Tivantinib (Monotherapy or Combination)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Protocol Violation

   4. reasons

      1. group Id

         FG000

         num Subjects

         32

      type

      Progressive disease per RECIST

   5. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Progressive disease per clinician

   6. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Physician Decision

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      No reason provided

   9. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Drug manufacturing ended

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         60

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         60

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Adult male and female participants previously enrolled in phase 1 or phase 2 studies of tivantinib (ARQ 197) were eligible for enrollment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice